FDA OKs Qiagen's companion Dx tool to lung-cancer drug

07/15/2013 | Genetic Engineering & Biotechnology News

The FDA has approved Qiagen's Therascreen EGFR assay as a companion diagnostic to determine which patients are eligible to receive Boehringer Ingelheim's Gilotrif. Gilotrif, or afatinib, is a newly approved drug for patients with metastatic nonsmall-cell lung cancer who have exon 21 L858R substitution mutations and exon 19 deletions in the EGFR gene.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX